FLT3 and acute myeloid leukemia: Midostaurin resulted from a drug discovery effort to improve the protein kinase C inhibitory activity of Staurosporine [7] and targets constitutively activated mutant FMS-like tyrosine kinase-3 (FLT3), which is expressed in a subpopulation of patients with acute myeloid leukemia (AML) [8].